electroCore, Inc. has transitioned from a focus on prescription bioelectronic therapies toward expanding its portfolio of general wellness and human performance products, aiming to diversify revenue beyond heavily concentrated government healthcare contracts. Despite ongoing operating losses and liquidity challenges, the company is investing in commercial infrastructure and direct-to-consumer sales channels to drive growth. A patent infringement lawsuit with UAB Pulsetto poses legal uncertainty and potential financial burden. Regulatory complexities and reimbursement hurdles further complicate market penetration, underscoring risks tied to supplier single sourcing and payor coverage. Monitoring developments in litigation outcomes, market acceptance of new wellness offerings, and execution of commercialization strategies will be critical in 2026.